The non-hemostatic aspects of transfused platelets

Frontiers in Medicine

Volumn 5, Issue FEB, 2018, Pages

  Sut, Caroline ^a,b   Tariket, Sofiane ^a,b   Aubron, Cécile ^c   Aloui, Chaker ^a   Hamzeh Cognasse, Hind ^a   Berthelot, Philippe ^a   Laradi, Sandrine ^a,b   Greinacher, Andreas ^d   Garraud, Olivier ^a,e   Cognasse, Fabrice ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

CD40L; Inflammation; Innate immunity; Platelets; Serious adverse reaction; Transfusion

Indexed keywords

EID: 85050086844     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2018.00042     Document Type: Review

References (125)

1. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol (2011) 11(4):264-74. doi:10.1038/nri2956
2. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol (2012) 8(9):534-42. doi:10.1038/nrrheum.2012.118
3. Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and inflammation. Nat Immunol (2013) 14(8):768-70. doi:10.1038/ni.2666
4. Garraud O, Hamzeh-Cognasse H, Cognasse F. Platelets and cytokines: how and why? Transfus Clin Biol (2012) 19(3):104-8. doi:10.1016/j.tracli.2012.02.004
5. Garraud O, Hamzeh-Cognasse H, Pozzetto B, Cavaillon JM, Cognasse F. Bench-to-bedside review: platelets and active immune functions-new clues for immunopathology? Crit Care (2013) 17(4):236. doi:10.1186/cc12716
6. Whiteheart SW. Platelet granules: surprise packages. Blood (2011) 118(5):1190-1. doi:10.1182/blood-2011-06-359836
7. Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Fox L, Klement GL, et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol (2010) 85(7):487-93. doi:10.1002/ajh.21732
8. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol (2013) 35(3):254-61. doi:10.1111/ijlh.12084
9. Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. Semin Thromb Hemost (2016) 42(3):191-204. doi:10.1055/s-0035-1564835
10. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem (1987) 164(1):189-95. doi:10.1111/j.1432-1033.1987.tb11010.x
11. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol (2014) 12(6):426-37. doi:10.1038/nrmicro3269
12. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev (2009) 23(4):177-89. doi:10.1016/j.blre.2009.04.001
13. Thon JN, Italiano JE. Platelets: production, morphology and ultrastructure. Handb Exp Pharmacol (2012) 210:3-22. doi:10.1007/978-3-642-29423-5_1
14. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res (1999) 95(1):1-18. doi:10.1016/S0049-3848(99)00015-8
15. Garraud O, Tariket S, Sut C, Haddad A, Aloui C, Chakroun T, et al. Transfusion as an inflammation hit: knowns and unknowns. Front Immunol (2016) 7:534. doi:10.3389/fimmu.2016.00534
16. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 391(6667):591-4. doi:10.1038/35393
17. Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet (2001) 357(9273):2023-4. doi:10.1016/S0140-6736(00)05108-4
18. Freedman JE. CD40-CD40L and platelet function: beyond hemostasis. Circ Res (2003) 92(9):944-6. doi:10.1161/01.RES.0000074030.98009.FF
19. Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res (2009) 45(2-3):251-60. doi:10.1007/s12026-009-8106-9
20. Damien P, Cognasse F, Lucht F, Suy F, Pozzetto B, Garraud O, et al. Highly active antiretroviral therapy alters inflammation linked to platelet cytokines in HIV-1-infected patients. J Infect Dis (2013) 208(5):868-70. doi:10.1093/infdis/jit260
21. Berthet J, Damien P, Hamzeh-Cognasse H, Arthaud CA, Eyraud MA, Zeni F, et al. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. Clin Immunol (2012) 145(3):189-200. doi:10.1016/j.clim.2012.09.004
22. McNicol A, Agpalza A, Jackson EC, Hamzeh-Cognasse H, Garraud O, Cognasse F. Streptococcus sanguinis-induced cytokine release from platelets. J Thromb Haemost (2011) 9(10):2038-49. doi:10.1111/j.1538-7836.2011.04462.x
23. Cognasse F, Hamzeh-Cognasse H, Berthet J, Damien P, Lucht F, Pozzetto B, et al. Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides. AIDS (2009) 23(15):2057-9. doi:10.1097/QAD.0b013e328330da65
24. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. J Immunol (2015) 194(12):5579-87. doi:10.4049/jimmunol.1500259
25. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol (2005) 238(1):1-9. doi:10.1016/j.cellimm.2005.12.005
26. Cognasse F, Garraud O, Pozzetto B, Laradi S, Hamzeh-Cognasse H. How can non-nucleated platelets be so smart? J Thromb Haemost (2016) 14(4):794-6. doi:10.1111/jth.13262
27. Garraud O, Cognasse F. Are platelets cells? And if yes, are they immune cells? Front Immunol (2015) 6:70. doi:10.3389/fimmu.2015.00070
28. Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules or not? J Thromb Haemost (2015) 13(12):2141-51. doi:10.1111/jth.13147
29. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation (2002) 106(8):896-9. doi:10.1161/01.CIR.0000028962.04520.01
30. Cognasse F, Payrat JM, Corash L, Osselaer JC, Garraud O. Platelet components associated with acute transfusion reactions: the role of platelet-derived soluble CD40 ligand. Blood (2008) 112(12):4779-80. doi:10.1182/blood-2008-05-157578
31. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science (2010) 327(5965):580-3. doi:10.1126/science.1181928
32. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood (2001) 98(4):1047-54. doi:10.1182/blood.V98.4.1047
33. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood (2006) 108(7):2455-62. doi:10.1182/blood-2006-04-017251
34. Perros AJ, Christensen AM, Flower RL, Dean MM. Soluble mediators in platelet concentrates modulate dendritic cell inflammatory responses in an experimental model of transfusion. J Interferon Cytokine Res (2015) 35(10):821-30. doi:10.1089/jir.2015.0029
35. Martinson J, Bae J, Klingemann HG, Tam Y. Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC. Cytotherapy (2004) 6(5):487-97. doi:10.1080/14653240410005249
36. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol (2009) 21(5):265-72. doi:10.1016/j.smim.2009.05.010
37. Elzey BD, Ratliff TL, Sowa JM, Crist SA. Platelet CD40L at the interface of adaptive immunity. Thromb Res (2011) 127(3):180-3. doi:10.1016/j.thromres.2010.10.011
38. Iannacone M. Platelet-mediated modulation of adaptive immunity. Semin Immunol (2016) 28(6):555-60. doi:10.1016/j.smim.2016.10.008
39. Aloui C, Prigent A, Sut C, Tariket S, Hamzeh-Cognasse H, Pozzetto B, et al. The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int J Mol Sci (2014) 15(12):22342-64. doi:10.3390/ijms151222342
40. Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol (2003) 1(2):157-69. doi:10.2174/1570161033476772
41. Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells. Transfus Med Hemother (2016) 43(2):78-88. doi:10.1159/000444807
42. Chapman LM, Aggrey AA, Field DJ, Srivastava K, Ture S, Yui K, et al. Platelets present antigen in the context of MHC class I. J Immunol (2012) 189(2):916-23. doi:10.4049/jimmunol.1200580
43. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 19(1):9-19. doi:10.1016/S1074-7613(03)00177-8
44. Garraud O, Chabert A, Hamzeh-Cognasse H, Laradi S, Cognasse F. Platelets and immunity: from physiology to pathology. Transfus Clin Biol (2017) 24(2):83-6. doi:10.1016/j.tracli.2017.04.004
45. Tariket S, Sut C, Hamzeh-Cognasse H, Laradi S, Pozzetto B, Garraud O, et al. Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers. Expert Rev Hematol (2016) 9(5):497-508. doi:10.1586/17474086.2016.1152177
46. Connell NT. Transfusion medicine. Prim Care (2016) 43(4):651-9. doi:10.1016/j.pop.2016.07.004
47. Funk M (ed). Chapter 27: non-infectious complications of blood transfusion. 18th ed. AABB Technical Manual. Bethesda: AABB (2014)
48. ANSM. Rapport d'activité hémovigilance 2015. (2016). Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/27ce3d0739821882c0cd87041b8050a7.pdf
49. Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician (2011) 83(6):719-24
50. Wagner T, Vetter A, Dimovic N, Guber SE, Helmberg W, Kroll W, et al. Ultrastructural changes and activation differences in platelet concentrates stored in plasma and additive solution. Transfusion (2002) 42(6):719-27. doi:10.1046/j.1537-2995.2002.00125.x
51. Osterman JL, Arora S. Blood product transfusions and reactions. Emerg Med Clin North Am (2014) 32(3):727-38. doi:10.1016/j.emc.2014.04.012
52. Hechler B, Ravanat C, Gachet C. Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance. Haematologica (2017) 102:e502-3. doi:10.3324/haematol.2017.180539
53. Tissot JD, Bardyn M, Sonego G, Abonnenc M, Prudent M. The storage lesions: from past to future. Transfus Clin Biol (2017) 24(3):277-84. doi:10.1016/j.tracli.2017.05.012
54. Wadhwa M, Krailadsiri P, Dilger P, Gaines Das R, Seghatchian MJ, Thorpe R. Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. Vox Sang (2002) 83(2):125-36. doi:10.1046/j.1423-0410.2002.00203.x
55. Cognasse F, Hamzeh-Cognasse H, Lafarge S, Acquart S, Chavarin P, Courbil R, et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro study. Transfusion (2009) 49(1):91-8. doi:10.1111/j.1537-2995.2008.01931.x
56. Silliman CC, Dickey WO, Paterson AJ, Thurman GW, Clay KL, Johnson CA, et al. Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion (1996) 36(2):133-9. doi:10.1046/j.1537-2995.1996.36296181925.x
57. Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R. The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage. Vox Sang (2003) 84(1):28-35. doi:10.1046/j.1423-0410.2003.00257.x
58. Zimring JC, Slichter S, Odem-Davis K, Felcyn JR, Kapp LM, Bell LN, et al. Metabolites in stored platelets associated with platelet recoveries and survivals. Transfusion (2016) 56(8):1974-83. doi:10.1111/trf.13631
59. Paglia G, Sigurjonsson OE, Rolfsson O, Valgeirsdottir S, Hansen MB, Brynjolfsson S, et al. Comprehensive metabolomic study of platelets reveals the expression of discrete metabolic phenotypes during storage. Transfusion (2014) 54(11):2911-23. doi:10.1111/trf.12710
60. Prudent M, D'Alessandro A, Cazenave JP, Devine DV, Gachet C, Greinacher A, et al. Proteome changes in platelets after pathogen inactivation-an interlaboratory consensus. Transfus Med Rev (2014) 28(2):72-83. doi:10.1016/j.tmrv.2014.02.002
61. Rosenfeld BA, Herfel B, Faraday N, Fuller A, Braine H. Effects of storage time on quantitative and qualitative platelet function after transfusion. Anesthesiology (1995) 83(6):1167-72. doi:10.1097/00000542-199512000-00006
62. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM. Platelet transfusions for critically ill patients with thrombocytopenia. Blood (2014) 123(8):1146-51; quiz 280. doi:10.1182/blood-2013-02-435693
63. Vlaar AP, Hofstra JJ, Kulik W, van Lenthe H, Nieuwland R, Schultz MJ, et al. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model. Blood (2010) 116(8):1360-8. doi:10.1182/blood-2009-10-248732
64. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood (2005) 105(10):4106-14. doi:10.1182/blood-2003-08-2724
65. Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, et al. Patient and product factors affecting platelet transfusion results. Transfusion (2008) 48(4):681-7. doi:10.1111/j.1537-2995.2007.01613.x
66. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood (2012) 119(23):5553-62. doi:10.1182/blood-2011-11-393165
67. MacLennan S, Harding K, Llewelyn C, Choo L, Bakrania L, Massey E, et al. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2-to 5-versus 6-or 7-day-stored platelets. Transfusion (2015) 55(8):1856-65; quiz 5. doi:10.1111/trf.13038
68. Kreuger AL, Caram-Deelder C, Jacobse J, Kerkhoffs JL, van der Bom JG, Middelburg RA. Effect of storage time of platelet products on clinical outcomes after transfusion: a systematic review and meta-analyses. Vox Sang (2017) 112(4):291-300. doi:10.1111/vox.12494
69. Welsby IJ, Lockhart E, Phillips-Bute B, Campbell ML, Mathew JP, Newman MF, et al. Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion (2010) 50(11):2311-7. doi:10.1111/j.1537-2995.2010.02747.x
70. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Spinella PC, et al. Impact of the duration of platelet storage in critically ill trauma patients. J Trauma (2011) 71(6):1766-73; discussion 73-4. doi:10.1097/TA.0b013e31823bdbf9
71. Juffermans NP, Vlaar AP, Prins DJ, Goslings JC, Binnekade JM. The age of red blood cells is associated with bacterial infections in critically ill trauma patients. Blood Transfus (2012) 10(3):290-5. doi:10.2450/2012.0068-11
72. Juffermans NP, Prins DJ, Vlaar AP, Nieuwland R, Binnekade JM. Transfusion-related risk of secondary bacterial infections in sepsis patients: a retrospective cohort study. Shock (2011) 35(4):355-9. doi:10.1097/SHK.0b013e3182086094
73. Flint A, Aubron C, Bailey M, Bellomo R, Pilcher D, Cheng AC, et al. Duration of platelet storage and outcomes of critically ill patients. Transfusion (2017) 57(3):599-605. doi:10.1111/trf.14056
74. Aubron C, Flint AW, Bailey M, Pilcher D, Cheng AC, Hegarty C, et al. Is platelet transfusion associated with hospital-acquired infections in critically ill patients? Crit Care (2017) 21(1):2. doi:10.1186/s13054-016-1593-x
75. Engele LJ, Straat M, van Rooijen IHM, de Vooght KMK, Cremer OL, Schultz MJ, et al. Transfusion of platelets, but not of red blood cells, is independently associated with nosocomial infections in the critically ill. Ann Intensive Care (2016) 6(1):67. doi:10.1186/s13613-016-0173-1
76. Frazier SK, Higgins J, Bugajski A, Jones AR, Brown MR. Adverse reactions to transfusion of blood products and best practices for prevention. Crit Care Nurs Clin North Am (2017) 29(3):271-90. doi:10.1016/j.cnc.2017.04.002
77. Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2015) 373(3):252-61. doi:10.1056/NEJMcp1411910
78. Krauel K, Potschke C, Weber C, Kessler W, Furll B, Ittermann T, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood (2011) 117(4):1370-8. doi:10.1182/blood-2010-08-301424
79. Krauel K, Weber C, Brandt S, Zahringer U, Mamat U, Greinacher A, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood (2012) 120(16):3345-52. doi:10.1182/blood-2012-06-434985
80. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost (2017) 15(11):2099-114. doi:10.1111/jth.13813
81. Nguyen TH, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun (2017) 8:14945. doi:10.1038/ncomms14945
82. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol (2012) 34(1):151-65. doi:10.1007/s00281-011-0280-x
83. Delcea M, Greinacher A. Biophysical tools to assess the interaction of PF4 with polyanions. Thromb Haemost (2016) 116(5):783-91. doi:10.1160/TH16-04-0258
84. Cai Z, Yarovoi SV, Zhu Z, Rauova L, Hayes V, Lebedeva T, et al. Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nat Commun (2015) 6:8277. doi:10.1038/ncomms9277
85. Greinacher A, Holtfreter B, Krauel K, Gatke D, Weber C, Ittermann T, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood (2011) 118(5):1395-401. doi:10.1182/blood-2011-03-342857
86. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med (2001) 344(17):1286-92. doi:10.1056/NEJM200104263441704
87. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med (2008) 121(7):632-6. doi:10.1016/j.amjmed.2008.03.012
88. Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? J Thromb Haemost (2008) 6(9):1598-600. doi:10.1111/j.1538-7836.2008.03040.x
89. Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. J Thromb Haemost (2009) 7(3):499-501. doi:10.1111/j.1538-7836.2008.03263.x
90. Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood (2014) 123(23):3651-4. doi:10.1182/blood-2014-01-549741
91. Greinacher A. Me or not me? The danger of spontaneity. Blood (2014) 123(23):3536-8. doi:10.1182/blood-2014-04-566836
92. Perrin J, Barraud D, Toussaint-Hacquard M, Bollaert PE, Lecompte T. Rapid onset heparin-induced thrombocytopenia (HIT) without history of heparin exposure: a new case of so-called 'spontaneous' HIT. Thromb Haemost (2012) 107(4):795-7. doi:10.1160/TH11-12-0825
93. Okata T, Miyata S, Miyashita F, Maeda T, Toyoda K. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: atypical clinical features with heparin-dependent platelet activating antibodies. Platelets (2015) 26(6):602-7. doi:10.3109/09537104.2014.979338
94. Mallik A, Carlson KB, DeSancho MT. A patient with 'spontaneous' heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis (2011) 22(1):73-5. doi:10.1097/MBC.0b013e328340ff11
95. Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W, McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost (2013) 109(4):669-75. doi:10.1160/TH12-11-0865
96. Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med (2015) 372(5):492-4. doi:10.1056/NEJMc1414161
97. Brandt S, Krauel K, Jaax M, Renne T, Helm CA, Hammerschmidt S, et al. Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria. Thromb Haemost (2015) 114(6):1189-98. doi:10.1160/TH15-01-0062
98. Antczak AJ, Vieth JA, Singh N, Worth RG. Internalization of IgG-coated targets results in activation and secretion of soluble CD40 ligand and RANTES by human platelets. Clin Vaccine Immunol (2011) 18(2):210-6. doi:10.1128/CVI.00296-10
99. Worth RG, Chien CD, Chien P, Reilly MP, McKenzie SE, Schreiber AD. Platelet FcgammaRIIA binds and internalizes IgG-containing complexes. Exp Hematol (2006) 34(11):1490-5. doi:10.1016/j.exphem.2006.06.015
100. Riaz AH, Tasma BE, Woodman ME, Wooten RM, Worth RG. Human platelets efficiently kill IgG-opsonized E. coli. FEMS Immunol Med Microbiol (2012) 65(1):78-83. doi:10.1111/j.1574-695X.2012.00945.x
101. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood (2002) 99(11):4021-9. doi:10.1182/blood-2001-12-0191
102. White JG. Why human platelets fail to kill bacteria. Platelets (2006) 17(3):191-200. doi:10.1080/09537100500441234
103. White JG. Platelets are covercytes, not phagocytes: uptake of bacteria involves channels of the open canalicular system. Platelets (2005) 16(2):121-31. doi:10.1080/09537100400007390
104. Peters CG, Michelson AD, Flaumenhaft R. Granule exocytosis is required for platelet spreading: differential sorting of alpha-granules expressing VAMP-7. Blood (2012) 120(1):199-206. doi:10.1182/blood-2011-10-389247
105. Palankar R, Kohler TP, Krauel K, Wesche J, Hammerschmidt S, Greinacher A. Platelets kill bacteria by bridging innate and adaptive immunity via PF4 and FcgammaRIIA. J Thromb Haemost (2018). doi:10.1111/jth.13955
106. Basu R, Whitlock BM, Husson J, Le Floc'h A, Jin W, Oyler-Yaniv A, et al. Cytotoxic T cells use mechanical force to potentiate target cell killing. Cell (2016) 165(1):100-10. doi:10.1016/j.cell.2016.01.021
107. Assinger A. Platelets and infection-an emerging role of platelets in viral infection. Front Immunol (2014) 5:649. doi:10.3389/fimmu.2014.00649
108. Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O. Platelets and infections-complex interactions with bacteria. Front Immunol (2015) 6:82. doi:10.3389/fimmu.2015.00082
109. Speth C, Rambach G, Lass-Florl C. Platelet immunology in fungal infections. Thromb Haemost (2014) 112(4):632-9. doi:10.1160/TH14-01-0074
110. McMorran BJ, Wieczorski L, Drysdale KE, Chan JA, Huang HM, Smith C, et al. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science (2012) 338(6112):1348-51. doi:10.1126/science.1228892
111. Arman M, Krauel K, Tilley DO, Weber C, Cox D, Greinacher A, et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3, and platelet factor 4. Blood (2014) 123(20):3166-74. doi:10.1182/blood-2013-11-540526
112. Moriarty RD, Cox A, McCall M, Smith SGJ, Cox D. Escherichia coli induces platelet aggregation in an FcγRIIa-dependent manner. J Thromb Haemost (2016) 14(4):797-806. doi:10.1111/jth.13226
113. Watson CN, Kerrigan SW, Cox D, Henderson IR, Watson SP, Arman M. Human platelet activation by Escherichia coli: roles for FcgammaRIIA and integrin alphaIIbbeta3. Platelets (2016) 27(6):535-40. doi:10.3109/09537104.2016.1148129
114. Kerrigan SW, Cox D. Platelet-bacterial interactions. Cell Mol Life Sci (2010) 67(4):513-23. doi:10.1007/s00018-009-0207-z
115. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun (2002) 70(12):6524-33. doi:10.1128/IAI.70.12.6524-6533.2002
116. Trier DA, Gank KD, Kupferwasser D, Yount NY, French WJ, Michelson AD, et al. Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun (2008) 76(12):5706-13. doi:10.1128/IAI.00935-08
117. Kraemer BF, Campbell RA, Schwertz H, Cody MJ, Franks Z, Tolley ND, et al. Novel anti-bacterial activities of beta-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog (2011) 7(11):e1002355. doi:10.1371/journal.ppat.1002355
118. Dasararaju R, Marques MB. Adverse effects of transfusion. Cancer Control (2015) 22(1):16-25. doi:10.1177/107327481502200104
119. Sahu S, Hemlata, Verma A. Adverse events related to blood transfusion. Indian J Anaesth (2014) 58(5):543-51. doi:10.4103/0019-5049.144650
120. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol (2015) 171(3):297-305. doi:10.1111/bjh.13597
121. Lubenow N, Eichler P, Albrecht D, Carlsson LE, Kothmann J, Rossocha WR, et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res (2000) 100(3):115-25. doi:10.1016/S0049-3848(00)00311-X
122. Zeller M, Canadian Blood Services. Chapter18: platelet transfusion-alloimmunization and management of platelet refractorisness. Clinical Guide to Transfusion. (2016). Available from: https://professionaleducation.blood.ca/en/transfusion/clinical-guide/platelet-transfusion-alloimmunization-and-management-platelet
123. Cid J, Carbasse G, Pereira A, Sanz C, Mazzara R, Escolar G, et al. Platelet transfusions from D+ donors to D-patients: a 10-year follow-up study of 1014 patients. Transfusion (2011) 51(6):1163-9. doi:10.1111/j.1537-2995.2010.02953.x
124. Chambost H. [Platelet transfusion and immunization anti-Rh1: implication for immunoprophylaxis]. Transfus Clin Biol (2014) 21(4-5):210-5. doi:10.1016/j.tracli.2014.08.137
125. Valsami S, Dimitroulis D, Gialeraki A, Chimonidou M, Politou M. Current trends in platelet transfusions practice: the role of ABO-RhD and human leukocyte antigen incompatibility. Asian J Transfus Sci (2015) 9(2):117-23. doi:10.4103/0973-6247.162684